Xoma Corporation

Xoma Technology Ltd.

Other

Xoma (us) LLC

US Government As Represented by the Secretary of the Army

Patrick J Scannon

Alan M Solinger

Nancy Wedel

Brett P Giroir

Robert Bauer

Nadav Friedmann

Alfred C Dadson, Jr

Marijke A Von Der Mohlen

Sander J Van Deventer

Frank Bernard

Robert S Tenerowicz

Robert W Baldwin

Vera S Byers

Marijke A M Von Der Mohlen

Sander J H Van Deventer

Roger G Little, Ii

Ronald P Mischak

Lynn E Spitler

John C Klock, Jr

Edward Lim

Lewis J Lambert, Jr

Howard M Lee

Russell T Kawahata

Paul R Sohmer

C Harold Mielke

Jeffrey D Feldstein

Robert J Bauer

David Alleva

Alfred C Dadson

Disclosed are methods for the reduction, prevention or treatment of cardiovascular events and/or cardiovascular diseases, including acute cardiovascular disease or chronic cardiovascular disease using anti-IL-1&#x3b2; binding molecules (e.g., IL-1&#x3b2; binding antibodies and fragments thereof). The present disclosure also relates to methods for prevention or treatment of cardiovascular events and/or cardiovascular diseases, including by reducing a cardiovascular event or disease.

Cardiovascular related uses of IL-1&#x3b2; antibodies and binding fragments thereof

A flexible, multi-product, multi-technology, expandable facility for manufacturing products, such as biologicals, pharmaceuticals, or chemicals, and manufacturing processes using elements of such a facility.

Flexible manufacturing system

Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, obesity, hyperglycemia, hyperinsulinemia and Type 1 diabetes, comprising administering to a subject an effective amount of anti-IL-1&#x3b2; antibody or fragment thereof.

Methods for the treatment of IL-1&#x3b2; related diseases

Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, decreased insulin production, hyperglycemia, hypoinsulinemia, metabolic syndrome, Type 1 diabetes and obesity, comprising administering to a subject an effective amount of anti-IL-1&#x3b2; antibody or fragment thereof.

Methods for treating IL-1&#x3b2; related diseases by administering an anti-IL-1&#x3b2; antibody

Disclosed are methods for improvement of beta cell function in a subject using an anti-IL-1&#x3b2; antibody or fragment thereof.

Methods for improvement of beta cell function with anti-IL-1&#x3b2; antibodies or fragments thereof

New therapeutic uses for BPI protein products that involve treatment of chronic cardiac disease.

Method of treating chronic cardiac disease

Methods and materials for the treatment of human meningococcemia are provided in which therapeutically effective amounts of BPI protein products are administered.

Therapeutic uses of BPI protein products for human meningococcemia

Disclosed are methods for treatment of humans exposed to bacterial endotoxin in circulation by administration of bactericidal/permeability-increasing (BPI) protein products. Serologically and hematologically verifiable alleviation of endotoxin mediated increases in circulating cytokines, fibrinolysis and coagulation factors and changes in lymphocyte counts are observed upon such treatment. Also observed is alleviation of endotoxin mediated decreases in systemic vascular resistance index (SVRI) and concomitant increases in cardiac index (CI).

Human therapeutic uses of BPI protein products

Growing community of inventors

San Francisco, CA, United States of America

Patrick J Scannon